Prior information notice: 2614 PAH

The contracting authorities for this competition are Sykehusinnkjøp HF, division pharmaceuticals on behalf of the four regional health companies in Norway: Helse Sør-Øst RHF, Helse Vest RHF, Helse Midt-Norway RHF and Helse Nord RHF. Sykehusinnkjøp HF, division pharmaceuticals have started the work of planning a new procurement of pharmaceutical special preparations for the treatment of pulmonary arterial hypertension (PAH). In the tender documentation for the procurement 2414 PAH we wrote in chapter 1.2.3 Presentation of contract prices for tenders for lots 2, 6 and 7 that "In order to strengthen and maintain competition in the market, division medicines for lot 2 bosentan, 6 sildenafil and 7 tadalafil will highlight all contract prices in the 2414 PAH procurement. This will occur at the earliest 12 months after the tender deadline for planning the start of a new tender competition for the active substances. Division medicinal products will then highlight the contract prices included in the mentioned lot in a prior information notice. When submitting a tender, tenderers therefore agree that division medicines can choose to highlight the contract prices for the mentioned lots." Prices (RHF-GIP) for the three above mentioned lots are attached in this prior information notice. The existing contract 2414 PAH will be valid until january 2026. Sykehusinnkjøp HF, division pharmaceuticals plans to invite interested parties to dialogue meetings in January/February 2025 in connection with the start of the procurement 2614 PAH, and an invitation to such dialogue meetings will be published in this notice.